• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
Home News & Views

News & Views

FILTER:
All ASX BD&AM BDAM Clinical Events News Prostate Cancer Awareness Month Scientific Publication Uncategorized

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer.
Read more

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.
Read more

First Patient Dosed in STARSTRUCK Study

Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is being conducted in patients with solid tumours expressing carbonic-anhydrase IX (CAIX), a potential pan-cancer target.  
Read more

Telix Quarterly Results and Investor Call / Webcast Notification

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market close.
Read more

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).
Read more

Telix Urology Innovation Showcase Webcast

Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City.
Read more

Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting being held in Chicago from June 24 – 27.
Read more

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical

Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals.
Read more

Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT and via live webcast (10.30pm AEST). The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures and will focus on:
Read more

First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Telix today announces that the first patient has been dosed in a global Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications.
Read more

Posts pagination

Previous page 1 … 24 25 26 … 54 Next page
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Telix Hotline
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”